MAP2K7 and familial pancreatic carcinoma: Thus, with the emergence of small molecule inhibitors targeting MEK, an integral enzyme of the RAS/RAF/MEK/ERK pathway, pancreatic cancer patients were actively accrued onto initial MEK inhibitor studies including trials with selumetinib [9, 10].